Nootropic and Neurotrophic Peptides
4 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- DavunetideDavunetide (also called NAP, AL‑108, AL‑208) is an eight‑amino‑acid peptide derived from the activity‑dependent neuroprotective protein (ADNP). It is being investigated as an investigational neuroprotective agent for neurodegenerative conditions such as Alzheimer’s disease, progressive supranuclear palsy, frontotemporal dementia and for cognitive impairment in schizophrenia. The compound is not approved for any indication and is studied primarily via intranasal, intravenous or subcutaneous administration.
- GlypromateGlypromate (glycyl‑l‑prolyl‑l‑glutamic acid, GPE) is an endogenous tripeptide found in the brain that has been investigated for neuroprotective properties. Research has focused on its ability to mitigate cellular damage in models of neurodegeneration and post‑surgical cognitive decline. Because of rapid degradation and limited brain penetration, most work explores chemical conjugates or delivery strategies to improve its pharmacokinetic profile. The compound remains in the research stage and is not approved for clinical use.
- NNZ-2591NNZ-2591 is a synthetic analogue of the endogenous diketopiperazine cyclic Gly‑Pro, derived from the insulin‑like growth factor‑1 (IGF‑1) metabolite. It is being investigated as a neuroprotective and neurotrophic agent for rare neurodevelopmental disorders such as Phelan‑McDermid syndrome and for a range of neurological injuries in pre‑clinical models.
- OmberacetamOmberacetam, also known as Noopept, GVS‑111, or N‑phenylacetyl‑L‑prolylglycine ethyl ester, is a synthetic dipeptide marketed as a prescription nootropic. It is classified with racetams but has a distinct structure. The drug is approved for clinical use in some jurisdictions and is administered orally, intranasally, or sublingually to support cognitive function and provide neuroprotective effects.